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In the striatum, dopamine D1 receptors are preferentially expressed in striatonigral neu-
rons, and increase the neuronal excitability, leading to the increase in GABAergic inhibitory
output to substantia nigra pars reticulata. Such roles of D1 receptors are important for the
control of motor functions. In addition, the roles of D1 receptors are implicated in reward,
cognition, and drug addiction. Therefore, elucidation of mechanisms for the regulation of
dopamine D1 receptor signaling is required to identify therapeutic targets for Parkinson’s
disease and drug addiction. D1 receptors are coupled to Gs/olf/adenylyl cyclase/PKA signal-
ing, leading to the phosphorylation of PKA substrates including DARPP-32. Phosphorylated
form of DARPP-32 atThr34 has been shown to inhibit protein phosphatase-1, and thereby
controls the phosphorylation states and activity of many downstream physiological effec-
tors. Roles of DARPP-32 and its phosphorylation at Thr34 and other sites in D1 receptor
signaling are extensively studied. In addition, functional roles of the non-canonical D1 recep-
tor signaling cascades that coupled to Gq/phospholipase C or Src family kinase become
evident. We have recently shown that phosphodiesterases (PDEs), especially PDE10A,
play a pivotal role in regulating the tone of D1 receptor signaling relatively to that of D2
receptor signaling.We review the current understanding of molecular mechanisms for the
modulation of D1 receptor signaling in the striatum.
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INTRODUCTION
Dopamine plays critical roles in the regulation of psychomo-
tor functions in the brain (Bromberg-Martin et al., 2010; Cools,
2011; Gerfen and Surmeier, 2011). The dopamine receptors are
a superfamily of heptahelical G protein-coupled receptors, and
are grouped into two categories, D1-like (D1, D5) and D2-like
(D2, D3, D4) receptors, based on functional properties to stim-
ulate adenylyl cyclase (AC) via Gs/olf and to inhibit AC via Gi/o,
respectively (Kebabian and Calne, 1979; Jackson and Westlind-
Danielsson, 1994; Missale et al., 1998). In the striatum, dopamine
D1 and D2 receptor expressions are segregated in two types
of medium spiny neurons, striatonigral/direct and striatopalli-
dal/indirect pathway neurons, respectively (Hersch et al., 1995;
Surmeier et al., 1996; Valjent et al., 2009; Bertran-Gonzalez et al.,
2010). In the striatonigral/direct pathway neurons, D1 receptors
are coupled to Gs/olf/AC/PKA signaling, and activation of PKA
induces the phosphorylation of PKA substrates such asDARPP-32,
a dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa,
and a transcription factor,CREB, leading to alterations of neuronal
functions (Greengard et al., 1999; Hyman and Malenka, 2001). In
this review, the roles of DARPP-32 and its phosphorylation in D1
receptor signaling and the recent ﬁndings on the modulation of
D1 receptor/Gs/olf/AC/PKA signaling by phosphodiesterase (PDE)
inhibitors are discussed. In addition, the non-canonical D1 recep-
tor signaling cascades that couple to Gq/phospholipase C (PLC)
or Src family kinase (SFK) are overviewed.
ROLES OF DARPP-32 AND ITS PHOSPHORYLATION IN D1
RECEPTOR/Gs/olf/AC/cAMP/PKA SIGNALING
ROLE OF THE PKA PHOSPHORYLATION-SITE AT Thr34 OF DARPP-32
Dopamine, acting on D1 receptors, stimulates cAMP/PKA signal-
ing via Gs/olf-mediated activation of AC (Herve et al., 2001). In
postsynaptic striatal neurons, DARPP-32 is a major target for the
cAMP/PKA signaling cascade (Greengard et al., 1999; Svennings-
son et al., 2004). DARPP-32 is expressed in D1 receptor-enriched
striatonigral neurons as well as D2 receptor-enriched striatopal-
lidal neurons (Bateup et al., 2008). Phosphorylation at Thr34
by PKA converts DARPP-32 into a potent inhibitor of protein
phosphatase-1 (PP-1; Figure 1). The inhibition of PP-1 thereby
controls the phosphorylation state and activity of many down-
stream physiological effectors, including various neurotransmitter
receptors (e.g., AMPA receptor GluR1 subunit, NMDA receptor
NR1 subunit), ion channels and pumps (e.g.,N/P-typeCa2+ chan-
nels, Na+ channel, Na+, K+-ATPase), and transcription factors
(e.g., CREB, c-Fos, FosB). Especially in cases of dual substrates
for PKA and PP-1 such asGluR1 at Ser845 andNR1 at Ser897, acti-
vation of PKA signaling can efﬁciently increase the phosphoryla-
tion states of such substrates.Mice lackingDARPP-32 are deﬁcient
in their molecular, electrophysiological, and behavioral responses
to dopamine, drugs of abuse, and antipsychotic medication, indi-
cating an essential role for DARPP-32 in dopaminergic signaling
(Fienberg et al., 1998; Fienberg and Greengard, 2000). Recently,
a study using DARPP-32 conditional knockout mice, in which
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FIGURE 1 |The D1 receptor signaling cascades in striatonigral/direct
pathway neurons. D1 receptors couple to at least three distinct signaling
cascades: (1) Gs/olf/adenylyl cyclase (AC)/cAMP/PKA/DARPP-32/protein
phosphatase-1 (PP-1) signaling (blue; Svenningsson et al., 2004; Stipanovich
et al., 2008), (2) Gq/phospholipase C (PLC)/inositol 1,4,5-trisphosphate (IP3)/IP3
receptor/Ca2+ signaling (orange; Rashid et al., 2007a; Kuroiwa et al., 2008;
Hasbi et al., 2009), (3) Gβγ/Src family kinase (SFK)/NMDA receptor NR2B
subunit/Ca2+/Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1)/
mitogen-activated protein kinase/ERK kinase (MEK)/ERK signaling (green;
Girault et al., 2007; Pascoli et al., 2011). The phosphorylation levels of
DARPP-32 are low at Thr34 and high at Thr75, Ser97, and Ser130 under basal
conditions. Activation of PKA induces the phosphorylation of DARPP-32 at
Thr34 and the dephosphorylation of DARPP-32 at Thr75 and Ser97 by
PP-2A/B56δ complex, and phospho-Thr34/dephospho-Ser97 DARPP-32
accumulates in nucleus and inhibits PP-1, leading to the increase in histone
H3 phosphorylation (Stipanovich et al., 2008). ERK, activated by two D1
receptor pathways, induces mitogen- and stress-activated kinase 1 (MSK1)
activation and histone H3 and cAMP-response element binding protein
(CREB) phosphorylation in the nucleus (Girault et al., 2007; Pascoli et al.,
2011). Thus, D1 receptor-mediated activation of PKA, intracellular Ca2+, and
ERK signaling induces the changes in downstream signaling cascades and the
transcriptional activation of many genes. CaMK, Ca2+/calmodulin-dependent
protein kinase; DAG, diacylglycerol; PDE, phosphodiesterase; STEP,
striatal-enriched tyrosine phosphatase.
DARPP-32 is selectively deleted in D1 receptor-enriched striatoni-
gral or D2 receptor-enriched striatopallidal neurons, revealed that
DARPP-32 expressed in two types of medium spiny neurons dif-
ferentially regulates striatal motor behaviors (Bateup et al., 2010).
The loss of DARPP-32 in striatonigral neurons decreases basal
and cocaine-induced locomotor activities and attenuates l-DOPA-
induced dyskinesia in a 6-hydorxydopamine hemi-lesionedmodel
of Parkinson’s disease,whereas the loss of DARPP-32 in striatopall-
idal neurons increases basal and cocaine-induced locomotor activ-
ities and abolishes haloperidol-induced catalepsy. These ﬁndings
support the idea that DARPP-32 enhances D1 receptor functions
in striatonigral neurons, but opposes D2 receptor functions in
striatopallidal neurons.
The phosphorylation state of DARPP-32 at Thr34 is regulated
by the balance of phosphorylation by PKA and dephosphorylation
by protein phosphatase 2B (calcineurin) and 2A (PP-2A). PKA sig-
naling in direct pathway neurons is activated by β1-adrenceptors
(Hara et al., 2010) and 5-HT4/6 receptors (Svenningsson et al.,
2002, 2007) as well as D1 receptors (Bateup et al., 2008; Kuroiwa
et al., 2008), and is inhibited by adenosine A1 receptors (Yabuuchi
et al., 2006), α2-adrenceptors (Hara et al., 2010), and μ-opioid
receptors (Lindskog et al., 1999). Dephosphorylation of phospho-
Thr34 DARPP-32 is mainly regulated by calcineurin (Nishi et al.,
1999). Activation of NMDA or AMPA receptors increases intra-
cellular Ca2+ and activates calcineurin, leading to the dephos-
phorylation of DARPP-32 at Thr34 (Halpain et al., 1990; Nishi
et al., 1999). D2 receptors are known to activate calcineurin via
PLC/intracellular Ca2+ signaling (Hernandez-Lopez et al., 2000),
leading to the dephosphorylation of DARPP-32 at Thr34 in striatal
neurons where D1 and D2 receptors are co-expressed (Nishi et al.,
1997). PP-2A also contributes to control the dephosphorylation
process of DARPP-32 at Thr34 in a coordinated manner with cal-
cineurin, as inhibition of PP-2A and calcineurin induces the syner-
gistic and robust increase in DARPP-32 Thr34 phosphorylation in
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striatal slices (Nishi et al., 1999). However, the role of PP-2A in the
dephosphorylation of DARPP-32 at Thr34 is not fully understood
under physiological conditions.
ROLE OF THE Cdk5 PHOSPHORYLATION-SITE AT Thr75 OF DARPP-32
In addition to Thr34, DARPP-32 is phosphorylated at multiple
sites by several protein kinases. The major phosphorylation sites
are at Thr75 for cyclin-dependent kinase 5 (Cdk5; Bibb et al.,
1999), at Ser97 for CK2 (Girault et al., 1989), and at Ser130 for
CK1 (Desdouits et al., 1995b), and these sites are highly phospho-
rylated in intact cells. DARPP-32 phosphorylated at Thr75 inhibits
PKA activity and thereby reduces the efﬁcacy of dopamine D1
receptor signaling (Bibb et al., 1999). Dopamine, via dopamine
D1 receptors, activates PKA, which directly stimulates DARPP-
32 Thr34 phosphorylation, and indirectly stimulates DARPP-32
Thr75 dephosphorylation by PP-2A (Nishi et al., 2000). PP-2A
associated with B56δ regulatory subunit is involved in the dephos-
phorylation of Thr75. B56δ at Ser566 is phosphorylated by PKA,
and the phosphorylation increases the activity of PP-2A/B56δ
complex to dephosphorylate DARPP-32 at Thr75 (Ahn et al.,
2007a). The ability of activated PKA to reduce the phosphory-
lation state of DARPP-32 at Thr75 and thereby de-inhibit PKA is
important as a positive feedback mechanism for enhancing PKA
signaling (Nishi et al., 2000). Further activation of PKA and inhibi-
tion of PP-1 viaDARPP-32-dependentmechanisms synergistically
increase the phosphorylation of various substrates.
Glutamate acting on NMDA or AMPA receptors also stim-
ulates the dephosphorylation of DARPP-32 at Thr75 by PP-2A
(Nishi et al., 2002). PP-2A associated with B′′/PR72 regulatory
subunit mediates Ca2+-dependent dephosphorylation of Thr75
(Ahn et al., 2007b). PR72 contains two Ca2+-binding EF hands,
EF1 and EF2 (Janssens et al., 2003). EF2 likely promotes the assem-
bly of PP-2A/PR72 complex, and Ca2+ binding to EF1 activates
PP-2A/PR72 activity forDARPP-32 at Thr75 in a substrate-speciﬁc
manner (Janssens et al., 2003; Ahn et al., 2007b). By utilizing the
Ca2+-dependent PP-2A/PR72 pathway, glutamate increases PKA
activity by dephosphorylating Thr75 of DARPP-32, similarly to
the D1 receptor-activated PP-2A/B56δ pathway.
The importance of DARPP-32 Thr75 phosphorylation is impli-
cated in drug abuse. Chronic administration of psychostimulants
such as cocaine induces the accumulation of a transcription fac-
tor,FosB, resulting in the induction of a downstream target gene,
Cdk5 (Bibb et al., 2001). The induced Cdk5 increases DARPP-32
Thr75 phosphorylation and therefore decreases D1 receptor/PKA
signaling. The attenuation of D1 receptor/PKA signaling is con-
sidered as adaptive changes to cocaine addiction. The role of
DARPP-32 at Thr75 is also demonstrated in stimulatory action of
caffeine (Lindskog et al., 2002). Caffeine, by antagonizing adeno-
sineA2A receptors in striatopallidal neurons, attenuatesA2A recep-
tor/PKA signaling and PP-2A activity and subsequently increases
DARPP-32 Thr75 phosphorylation, which likely contribute to the
stimulatory action of caffeine.
ROLE OF THE CK2 PHOSPHORYLATION-SITE AT Ser97 OF DARPP-32 AND
THE CK1 PHOSPHORYLATION-SITE AT Ser130 OF DARPP-32
Phosphorylation of DARPP-32 at Ser97 (in mouse sequence;
Ser102 in rat sequence) by CK2 is reported to increase the efﬁ-
cacy of DARPP-32 Thr34 phosphorylation by PKA (Girault et al.,
1989). In parallel, phosphorylation of DARPP-32 at Ser130 (in
mouse sequence; Ser137 in rat sequence) by CK1 decreases the
rate of dephosphorylation of Thr34 by calcineurin (Desdouits
et al., 1995a). Thus, DARPP-32 phosphorylation by CK2 or CK1
results in the increase in the phosphorylation states of DARPP-
32 at Thr34, suggesting the role of CK2 and CK1 to enhance
D1 receptor/PKA/DARPP-32/PP-1 signaling cascade. However, an
opposing action of CK2 to inhibit D1 receptor/PKA signaling is
demonstrated (Rebholz et al., 2009). CK2 directly interacts with
Gs/olf , and negatively controls the functions of D1 receptors as well
as A2A receptors by enabling faster internalization.
Recently, the phosphorylation state of DARPP-32 at Ser97 is
found to be a key regulator of nuclear export of DARPP-32
(Stipanovich et al., 2008). DARPP-32 has been thought as cyto-
plasmic protein because majority of DARPP-32 was fractionated
in the soluble fraction (Walaas and Greengard, 1984), although
the immunoreactivity of DARPP-32 was noticed in some nuclei
of medium spiny neurons (Ouimet and Greengard, 1990). Impor-
tantly, activation of D1 receptor/PKA signaling induces the nuclear
accumulation of DARPP-32 (Stipanovich et al., 2008). The phos-
phorylation of DARPP-32 at Ser97 by CK2 functions as nuclear
export signal of DARPP-32. Ser97 is highly phosphorylated under
basal conditions (Girault et al., 1989), and only small fraction
of DARPP-32 is located in the nucleus. When PKA is acti-
vated, Ser97 is dephosphorylated by PKA-activated PP-2A/B56δ
complex, resulting in the accumulation of DARPP-32 (phospho-
Thr34/dephospho-Ser97 form of DARPP-32) in the nucleus. The
inhibition of PP-1 by phospho-Thr34 DARPP-32 promotes his-
tone H3 phosphorylation and regulates the nuclear function via
mechanisms of chromatin remodeling. These ﬁndings provide
mechanisms for D1 receptor/PKA/DARPP-32 signaling to regulate
gene expression, especially in conditions of drug addiction.
REGULATION OF D1 RECEPTOR/PKA/DARPP-32 SIGNALING BY
NEUROTRANSMITTERS
The D1 receptor/PKA/DARPP-32 signaling cascade is modulated
by various neurotransmitters including glutamate, GABA, acetyl-
choline, adenosine, serotonin, norepinephrine, nitric oxide, and
neuropeptides (opioids, cholecystokinin, and neurotensin), in
addition to dopamine (for the review, see Svenningsson et al.,
2004). The release of dopamine is also regulated by neurotrans-
mitters, therapeutic drugs, and drugs of abuse (Schmitz et al.,
2003; Sulzer, 2011). We recently reported the role of glutamate
(Nishi et al., 2005), PGE2 (Kitaoka et al., 2007), nitric oxide
(Tanda et al., 2009), and norepinephrine (Hara et al., 2010) in
the regulation of D1 receptor/PKA/DARPP-32 signaling. The role
of DARPP-32 in integrating dopamine and other neurotransmit-
ter signaling in D1-type striatonigral neurons as well as D2-type
striatopallidal neurons has been proposed (Svenningsson et al.,
2004; Fernandez et al., 2006). Furthermore, alterations of the D1
receptor/PKA/DARPP-32 signaling cascade in drug addiction and
l-DOPA-induced dyskinesia are characterized (for the review, see
Svenningsson et al., 2005; Borgkvist and Fisone, 2007; Fisone et al.,
2007; Shuto and Nishi, 2011).
Dopamine D1 receptors are known to interact and form
hetero-oligomers with other neurotransmitter receptors such as
dopamine D2 receptors (Lee et al., 2004; Rashid et al., 2007b),
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dopamine D3 receptors (Fiorentini et al., 2008; Marcellino et al.,
2008), adenosineA1 receptors (Gines et al., 2000; Toda et al., 2003),
and NMDA receptors (Lee et al., 2002), resulting in alteration of
D1 receptor functions (Figure 2). The role of D1 receptor hetero-
oligomerization will be discussed in other reviews of this special
topic.
D1 RECEPTOR/Gq/PLC/IP3 SIGNALING
In addition to the dopamine D1 (D1A) receptor that couples to
Gs/olf/AC, the presence of a dopamine D1-like receptor that cou-
ples to Gq/PLC has been proposed (Felder et al., 1989; Undie and
Friedman, 1990; Wang et al., 1995; Beaulieu and Gainetdinov,
2011; Figure 1). D1-like receptors are shown to couple to both
Gs/AC and Gq/PLC signaling in the striatum and frontal cortex,
but solely to Gq/PLC signaling in the hippocampus and amygdala
(Undie and Friedman, 1990; Wang et al., 1995; Jin et al., 2001).
It has been reported that Gq/PLC-coupled D1-like receptors are
coded inmRNAwith different size from that of Gs/olf/AC-coupled
D1 receptors (Mahan et al., 1990), and are functional in dopamine
receptor D1A knockout mice (Friedman et al., 1997; Tomiyama
et al., 2002), but not in dopamine D5 receptor knockout mice
(Sahu et al., 2009). However, there is a report showing the lack of
Gq activation in the striatal membrane from D1A receptor knock-
out mice (Rashid et al., 2007b). It still needs to be determined
whether the cloned D1A receptor (Drd1a), different types of D1-
like receptors such as the D5 receptor, or both couple(s) to Gq/PLC
signaling in the striatum.
It has been demonstrated that D1 receptors form the hetero-
oligomer with D2 receptors, and that the D1–D2 receptor hetero-
oligomer preferentially couples to Gq/PLC signaling (Rashid et al.,
2007a,b). The expression of dopamine D1 and D2 receptors are
largely segregated in direct and indirect pathway neurons in the
dorsal striatum, respectively (Gerfen et al., 1990; Hersch et al.,
1995; Heiman et al., 2008). However, some proportion of medium
spiny neurons are known to expresses both D1 and D2 recep-
tors (Hersch et al., 1995). Gene expression analysis using single
cell RT-PCR technique estimated that 40% of medium spiny neu-
rons express both D1 and D2 receptor mRNA (Surmeier et al.,
1996). Recently, analysis using drd1a-EGFP and drd2-EGFP bac-
terial artiﬁcial chromosome (BAC) mice revealed that D1 and
D2 receptors are co-expressed in medium spiny neurons at 5%
FIGURE 2 | D1 receptors form hetero-oligomers with other receptors.
Formation of hetero-oligomers with dopamine D1 receptors and other
receptors such as D2, D3, A1, and NMDA receptors is shown. Biding of
these receptors induces the changes in D1 receptor function and/or
localization.
in the dorsal striatum, 6% in the NAc core, and 17% in the
NAc shell (Bertran-Gonzalez et al., 2008). Therefore, D1 recep-
tors likely interact with D2 receptors in some populations of
medium spiny neurons, where both D1 and D2 receptors are
co-expressed.
D1 and D2 receptors, co-expressed in transfected cells and stri-
atal neurons, form the hetero-oligomer (Lee et al., 2004). The
D1 and D2 receptor hetero-oligomer couples to Gq and activates
PLC and intracellular Ca2+ signaling (Lee et al., 2004; Rashid et al.,
2007b). For activation of Gq/PLC signaling, bothD1 andD2 recep-
tors are required, because either D1 or D2 antagonist and genetic
deletion of either D1 or D2 receptors abolish the effect (Rashid
et al., 2007b). It is likely that SKF83959, which selectively acti-
vate Gq/PLC signaling but not Gs/olf/PKA signaling, acts as a full
agonist for D1 receptors and a partial agonist for D2 receptors in
the form of hetero-oligomer (Rashid et al., 2007a,b). The func-
tional role of the D1 and D2 receptor hetero-oligomer to activate
Ca2+/calmodulin-dependent kinase IIα, which may lead to the
induction of brain-derived neurotrophic factor (BDNF) expres-
sion, has been suggested (Hasbi et al., 2009), and therefore the D1
and D2 receptor hetero-oligomer is implicated as a potential ther-
apeutic target for schizophrenia and drug addiction (Hasbi et al.,
2010).
The Gs/olf/AC-coupled and Gq/PLC-coupled D1-like recep-
tor signaling cascades likely play differential roles in dopamin-
ergic signaling. Gq/PLC-coupled D1-like receptors show dif-
ferent sensitivity to benzazepine dopamine D1 receptor ago-
nists from Gs/olf/AC-coupled D1 receptors (Undie et al., 1994).
Many D1 receptor agonists such as SKF38393 and SKF81297
activate both Gs/olf/AC and Gq/PLC signaling (Undie et al.,
1994). In contrast, SKF83959 preferentially stimulates Gq/PLC-
coupled D1-like receptors (Panchalingam and Undie, 2001; Jin
et al., 2003), and SKF83822 selectively stimulates Gs/olf/AC-
coupled D1 receptors (Undie et al., 1994). By utilizing SKF83959
and SKF83822, we investigated the D1-like receptor signal-
ing cascades, which regulate DARPP-32 phosphorylation at
Thr34 (the PKA-site) in mouse striatal slices (Kuroiwa et al.,
2008). Dopamine D1 receptor agonists activate at least three
D1-like receptor signaling cascades in striatonigral/direct path-
way neurons: (i) SCH23390-sensitive Gs/olf/AC/PKA signal-
ing, (ii) SCH23390-insensitive Gs/olf/AC/PKA signaling, and
(iii) Gq/PLC signaling. Activation of SCH23390-sensitive D1
receptors stimulates AC/cAMP/PKA signaling, leading to the
phosphorylation of DARPP-32 at Thr34 in striatonigral neu-
rons. Activation of Gq-coupled D1 receptors stimulates PLC
signaling, resulting in the suppression of DARPP-32 Thr34
phosphorylation.
Behavioral studies revealed that activation of D1 receptor/
Gs/olf/AC signaling by SKF83822 mediates snifﬁng, locomotion,
rearing, stereotypy, and seizure (O’Sullivan et al., 2004), whereas
activation of D1-like receptor/Gq/PLC signaling by SKF83959 as
well as SKF38393 mediates vacuous jaw movements and intense
grooming (Deveney and Waddington, 1995; Undie et al., 2000).
Molecular mechanisms by which Gq/PLC-coupled D1-like recep-
tors regulate the function of neostriatal neurons, and their interac-
tion with the D1 receptor/Gs/olf/AC/PKA signaling cascades need
to be clariﬁed.
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D1 RECEPTORS COUPLED TO Src FAMILY KINASE
SIGNALING
Activation of D1 receptors with simultaneous activation of NMDA
receptors by drugs of abuse such as cocaine and d-amphetamine
induces extracellular-signal regulated kinase (ERK) activation
selectively in striatonigral/direct pathway neurons (Valjent et al.,
2005; Bertran-Gonzalez et al., 2008), leading to activation of tran-
scription for genes critical for drug-induced plasticity (Girault
et al., 2007; Bertran-Gonzalez et al., 2008; Figure 1). The role of
D1 receptor/PKA/DARPP-32 signaling is also implicated for ERK
activation, since the inhibitionof PP-1 byphospho-Thr34DARPP-
32 induces activation of mitogen-activated protein kinase/ERK
kinase (MEK), which phosphorylates ERK, and inhibition of
striatal-enriched tyrosine phosphatase (STEP),which dephospho-
rylates ERK (Valjent et al., 2005; Girault et al., 2007). In addition,
the Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neu-
ronal speciﬁc activator of Ras/ERK signaling, is identiﬁed as an
upstream of MEK/ERK signaling (Fasano et al., 2009). However,
mechanisms for activation of NMDA receptors by drugs of abuse
were not clearly understood, because the changes in extracellular
glutamate levels induced by drugs of abuse were variable (Reid
et al., 1997; Zhang et al., 2001). Recently, Pascoli et al. (2011)
reported that D1 receptors potentiate NMDA receptor function
via phosphorylation of NR2B subunit (at Tyr1472) of NMDA
receptors by SFK, which is responsible for activation of the Ras-
GRF1/MEK/ERK signaling cascade by cocaine (Fasano et al., 2009;
Pascoli et al., 2011). The activation of SFK byD1 receptors is medi-
ated through Gβγ subunit. The ﬁndings are in agreement with
previous reports showing that D1 receptor-mediated increase in
NMDA receptor currents requires NR2B subunit and SFK activ-
ity (Wittmann et al., 2005), and that activation of D1 receptors
induces trafﬁcking of NMDA receptors to the postsynaptic mem-
branemediated throughNR2Bphosphorylation by SFK,especially
Fyn (Dunah and Standaert, 2001;Hallett et al., 2006). ThenovelD1
receptor/Gβγ/SFK/NR2B signaling cascade, which results in acti-
vation of NMDA receptors/Ca2+/Ras-GRF1/MEK/ERK signaling,
likely plays a critical role in pathological conditions such as drug
addiction and l-DOPA-induced dyskinesia in the animal model
of Parkinson’s disease, in which NR2B tyrosine phosphorylation
(Menegoz et al., 1995; Pascoli et al., 2011) and activation of ERK
signaling by D1 receptors (Gerfen et al., 2002; Girault et al., 2007;
Santini et al., 2007) are enhanced.
MODULATION OF cAMP/PKA SIGNALING IN D1-TYPE DIRECT
PATHWAY NEURONS AS WELLS AS D2-TYPE INDIRECT
PATHWAY NEURONS BY PHOSPHODIESTERASE (PDE)
INHIBITION
Activation of Gs/olf-coupled dopamine D1 receptors causes an
increase in cAMP synthesis, while the subsequent hydrolysis of
cAMP is mediated by PDEs. PDEs are subdivided into 11 fami-
lies, encoded by 21 genes (Conti and Beavo, 2007). Multiple PDEs
with different substrate speciﬁcities and subcellular localization
are expressed in the striatum. PDE10A, PDE1B, and PDE7B are
enriched in the striatum,andPDE4 (A,B, andD isoforms),PDE2A
and PDE9A, which are widely distributed in the brain, are also
expressed in the striatum (Menniti et al., 2006).
Several types of PDEs such as PDE10A, PDE4, and PDE1B are
expressed in direct and indirect pathway neurons. The inhibition
of PDEs can result in activation of cAMP/PKA signaling both in
direct and indirect pathway neurons. If the function of the PDE
(e.g., PDE1B) is predominant in direct pathway neurons, the inhi-
bition of the PDE and activation of cAMP/PKA signaling results
in activation of direct pathway neurons, leading to inhibition of
GPi/SNpr inhibitory output neurons and activation of thalamo-
corticalmotor circuits. Conversely, if the function of the PDE (e.g.,
PDE10A and PDE4) is predominant in indirect pathway neurons,
the inhibition of the PDE and activation of cAMP/PKA signal-
ing results in activation of indirect pathway neurons, leading to
activation of GPi/SNpr inhibitory output neurons and inhibition
of thalamocortical motor circuits. Thus, PDE inhibitors that pre-
dominantly act in direct pathway neurons work like dopamine
D1 receptor agonists and activate motor function, whereas PDE
inhibitors that predominantly act in indirect pathway neurons
work like dopamine D2 receptor antagonists and inhibit motor
function (Nishi and Snyder, 2010). The balance of action of each
PDE inhibitor in indirect and direct pathway neurons determines
the behavioral effects (Figure 3).
FIGURE 3 | Roles of phosphodiesterases (PDEs) in the control of basal
ganglia–thalamocortical circuitry. Output neurons in the striatum are
medium spiny neurons (MSNs), which consist of striatonigral/direct
pathway and striatopallidal/indirect pathway neurons. Direct pathway
neurons are GABAergic, and inhibit tonically active neurons in globus
pallidus interna (GPi)/substantia nigra pars reticulata (SNpr). Indirect
pathway neurons are also GABAergic, and activate neurons in GPi/SNpr via
inhibition of globus pallidus externa (GPe) GABAergic neurons and
activation of subthalamic nucleus (STN) glutamatergic neurons. Direct and
indirect pathway neurons induce opposing effects on the output neurons in
GPi/SNpr, resulting in dis-inhibition and pro-inhibition of output, respectively,
to motor areas of the thalamus and cortex. The inhibition of PDEs increases
cAMP/PKA signaling in both direct and indirect pathway neurons. PDE
inhibitors that predominantly act in direct pathway neurons work like
dopamine D1 receptor agonists and activate motor function, whereas PDE
inhibitors that predominantly act in indirect pathway neurons work like
dopamine D2 receptor antagonists and inhibit motor function. SNpc,
substantia nigra pars compacta. Reproduced with permission from
reference Nishi and Snyder (2010).
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ROLE OF PDE10A IN DOPAMINE SIGNALING
PDE10A is a dual substrate PDE that hydrolyzes both cAMP and
cGMP, and has a higher afﬁnity for cAMP than for cGMP by∼20-
fold (Fujishige et al., 1999; Bender and Beavo, 2006). In the stria-
tum, PDE10A is expressed in two types of medium spiny neurons
(direct and indirect pathway neurons), but not in interneurons
(Xie et al., 2006;Nishi et al., 2008; Sano et al., 2008). Papaverine, an
opium alkaloid primarily used for the treatment of visceral spasm
and vasospasm, was found to selectively inhibit PDE10A with an
IC50 of 36 nM(Siuciak et al., 2006). Papaverinewas used to explore
the physiological role of PDE10A in the regulation of striatal func-
tion. Recently, the potent PDE10A inhibitors, TP-10 (IC50 0.3 nM)
andMP-10 (IC50 0.18 nM), were developed (Schmidt et al., 2008).
Using these PDE10A inhibitors, PDE10A was shown to hydrolyze
both cAMP and cGMP in the striatum in vivo (Siuciak et al., 2006;
Schmidt et al., 2008; Grauer et al., 2009). We examined the effect
of papaverine on the phosphorylation of PKA substrates including
DARPP-32 using neostriatal slices. Papaverine robustly increased
the phosphorylation of DARPP-32 at Thr34 and GluR1 at Ser845
in striatal medium spiny neurons in slices as well as in vivo (Nishi
et al., 2008). The effect of papaverine was mediated through the
potentiation of cAMP/PKA signaling, but not cGMP/PKG sig-
naling. Similarly to papaverine, inhibition of PDE10A by TP-10
and/or MP-10 in the striatum in vivo was demonstrated to induce
the phosphorylation of DARPP-32,GluR1, andCREB at PKA-sites
(Schmidt et al., 2008; Grauer et al., 2009).
PDE10A is abundantly expressed in direct and indirect pathway
neurons, and the expression levels are similar in the two types of
neurons (Xie et al., 2006; Nishi et al., 2008; Sano et al., 2008). In
agreement, PDE10A regulates cAMP/PKA signaling (Nishi et al.,
2008) as well as gene expression (Strick et al., 2010) in both direct
and indirect pathwayneurons. In direct pathwayneurons,PDE10A
inhibition by papaverine activates cAMP/PKA signaling, leading
to the potentiation of dopamine D1 receptor signaling. In indirect
pathway neurons, PDE10A inhibition by papaverine also activates
cAMP/PKA signaling by simultaneously potentiating adenosine
A2A receptor signaling and inhibiting dopamine D2 receptor sig-
naling. Since the balance of cAMP/PKA signaling between the
direct and indirect pathways determines the output from the basal
ganglia, neuronal type-speciﬁc regulation of DARPP-32 Thr34
phosphorylation was studied using neostriatal slices from D1R-
DARPP-32-Flag/D2R-DARPP-32-Myc mice (Nishi et al., 2008),
in which Flag-tagged DARPP-32 and Myc-tagged DARPP-32 are
expressed selectively in direct and indirect pathway neurons under
the control of D1 and D2 receptor promoters, respectively (Bateup
et al., 2008). PDE10A inhibition by papaverine increases Myc-
tagged DARPP-32 phosphorylation sixfold in indirect pathways,
whereas Flag-tagged DARPP-32 phosphorylation only twofold
in direct pathway neurons. Thus, PDE10A inhibitors activate
cAMP/PKA signaling in indirect and direct pathway neurons, but
the action of PDE10A inhibitors predominates in indirect path-
way neurons. A recent electrophysiological study showing that
PDE10A inhibition has greater facilitatory effect on corticostri-
atal synaptic activity in indirect pathway neurons supports the
interpretation (Threlfell et al., 2009). The biochemical features of
PDE10A inhibitors resemble those of antipsychotic drugs, which
act primarily as D2 receptor antagonists and increase DARPP-32
phosphorylation in indirect pathway neurons (Bateup et al., 2008).
In agreement, PDE10A inhibition by papaverine, TP-10 and MP-
10 and genetic deletion of PDE10A display behavioral phenotypes
of antipsychotics with therapeutic potency for negative symptoms
and cognitive deﬁcits as well as positive symptoms in schizo-
phrenics (Sano et al., 2008; Grauer et al., 2009; Nishi and Snyder,
2010).
ROLE OF PDE4 IN DOPAMINE SIGNALING
PDE4 is a cAMP-speciﬁc PDE with high afﬁnity for cAMP (Km
1–10μM; Beavo, 1995; Bender and Beavo, 2006). The PDE4 fam-
ily is encoded by four genes (PDE4A–PDE4D), and each isoform
has multiple variants (Houslay and Adams, 2003; McCahill et al.,
2008). In the CNS, PDE4A, PDE4B, and PDE4D are widely dis-
tributed, but the expression of PDE4C is restricted to the olfactory
bulb in rodent brain (Cherry and Davis, 1999; Perez-Torres et al.,
2000). Each PDE4 variant has a modular structure consisting of a
variant-speciﬁc N-terminal domain, regulatory domains termed
upstream conserved region 1 (UCR1) and UCR2, and a cat-
alytic domain. The phosphorylation of UCR1 by PKA disrupts
the inhibitory interaction of UCR2 with the catalytic domain
and activates PDE4 activity (McCahill et al., 2008), leading to the
downregulation of cAMP/PKA signaling. The N-terminal domain
and UCR1/2 interact with PDE4 variant-speciﬁc binding pro-
teins including A-kinase anchor proteins (AKAP) and disrupted
in schizophrenia 1 (DISC1), leading to the compartmentalization
of cAMP signaling in cells (McCahill et al., 2008; Houslay, 2010).
The involvement of PDE4B in themolecularmechanisms of schiz-
ophrenia is supported by its interaction with DISC1 (Millar et al.,
2005;Clapcote et al., 2007;Murdoch et al., 2007),which is a genetic
susceptibility factor for schizophrenia (Chubb et al., 2008).
Function of PDE4 has been analyzed using a selective PDE4
inhibitor, rolipram (IC50 1μM; Bender and Beavo, 2006). Inhibi-
tion of PDE4 by rolipram robustly increases tyrosine hydroxylase
(TH) phosphorylation at Ser40 (PKA-site) at dopaminergic termi-
nals in neostriatal slices and in vivo, leading to the enhancement
of dopamine synthesis and metabolism (Nishi et al., 2008). In
addition, the inhibition of PDE4 by rolipram weakly enhances
cAMP/PKA signaling in striatal neurons, leading to the phospho-
rylation of DARPP-32 at Thr34 in neostriatal slices (Nishi et al.,
2008). Rolipram treatment augments adenosine A2A receptor-
mediated phosphorylation of DARPP-32 at Thr34, but has no
effect on dopamineD1 receptor-mediated phosphorylation. How-
ever, in neostriatal slices from D1R-Flag/D2R-Myc DARPP-32
mice, rolipram induces the phosphorylation of both Flag- and
Myc-tagged DARPP-32 in direct and indirect pathway neurons,
respectively. Immunohistochemical analysis in D1R-Flag/D2R-
Myc DARPP-32 mice revealed that PDE4B expression is higher
in indirect pathway neurons than that in direct pathway neurons.
These data suggest that PDE4 preferentially regulates cAMP/PKA
signaling coupled to adenosine A2A receptors in indirect path-
way neurons compared to that coupled to dopamine D1 receptors
in direct pathway neurons. Activation of cAMP/PKA signaling in
indirect pathway neurons elicited by the PDE4 inhibitor, rolipram,
is expected to oppose dopamine D2 receptor signaling. At the
same time, rolipram stimulates dopamine synthesis, indicating
that PDE4 inhibition raises dopaminergic tone in the striatum.
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Therefore, rolipram mimics the biochemical effects of dopamine
D2 antagonists and to some extent D1 agonists.
The pharmacological proﬁle of the PDE4 inhibitor, includ-
ing positive effects on mood and cognition, supports its possible
efﬁcacy for the treatment of negative symptoms and cognitive
deﬁcits in addition to positive symptoms in schizophrenics (Siu-
ciak, 2008). However, the studies in PDE4B knockout mice gener-
ally fail to recapitulate the antipsychotic effects of rolipram, and
the discrepancy might be explained by the lack of PDE4B selectiv-
ity of rolipram and chronic compensatorymechanisms for PDE4B
gene deletion (Siuciak, 2008; Nishi and Snyder, 2010).
ROLE OF PDE1B IN DOPAMINE SIGNALING
PDE1B is a dual substrate PDE with a higher afﬁnity for cGMP
(Km 2.4μM) than for cAMP (Km 24μM; Bender and Beavo,
2006). PDE1B is activated by Ca2+ and calmodulin, providing
a mechanism for crosstalk between Ca2+ and cyclic nucleotide
signaling. PDE1B is abundantly expressed in the striatum (Polli
and Kincaid, 1994), and striatal PDE1B is localized to all DARPP-
32-positive medium spiny neurons, indicating the PDE1B expres-
sion in both direct and indirect pathway neurons (A. Nishi and
M. Kuroiwa, unpublished observations). Biochemical studies in
PDE1B knockout mice revealed that the function of dopamine
D1 receptors to stimulate the phosphorylation of DARPP-32
and GluR1 at PKA-sites is potentiated in striatal slices from
PDE1B knockout mice (Reed et al., 2002). In behavioral analy-
sis, PDE1B knockout mice exhibited the increase in spontaneous
locomotor activity and psychostimulant- and NMDA receptor
antagonist-stimulated locomotor activity and the cognitive deﬁcit
in Morris water maze test (Reed et al., 2002; Ehrman et al., 2006;
Siuciak et al., 2007). In spite of similar expression pattern of
PDE1B with PDE10A in the striatum, the behavioral proﬁles of
PDE1B knockout mice are pro-psychotic and completely opposite
to those of PDE10A knockout mice. We hypothesize that PDE1B
predominantly regulates cyclic nucleotide signaling in direct path-
way neurons, whereas a predominant role of PDE10A and PDE4
in indirect pathway neurons.
CONCLUSION
D1 receptor signaling in striatonigral/direct pathway neurons plays
an essential role in motor functions (Gerfen and Surmeier, 2011)
as well as reward and cognition (Bromberg-Martin et al., 2010;
Cools, 2011). The alterations of D1 receptor signaling are impli-
cated in drug addiction (Shuto and Nishi, 2011) and l-DOPA-
induced dyskinesia (Fisone et al., 2007). Besides the importance
of D1 receptor signaling under pathophysiological conditions,
dopaminergic drugs are mainly acting on D2 receptors, and ther-
apeutic agents that selectively modulate D1 receptor signaling
are not currently utilized. Functional roles of the canonical and
non-canonical D1 receptor signaling cascades are implicated in
the same category of diseases. Further understanding of each
D1 receptor signaling cascade and its regulation is required for
the development of therapeutic agents targeting D1 receptor
signaling.
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